OrthoSera Medical Zrt.

OrthoSera Medical Zrt. is a Hungarian specialty pharmaceutical company based in Budapest that describes itself as Hungary's leading blood-serum development company. Its core premise is that blood serum — containing more than 200 proteins — carries a unique regenerative potential, chiefly through the activation of stem cells. By pairing the appropriate serum derivative with the right clinical indication, the company aims to trigger tissue remodeling and healing. The company has brought three independently developed technologies to clinical use. In orthopedics, it focuses on stem-cell-activating bone and joint regeneration serums intended to regenerate worn joints. In dentistry, it offers a serum-albumin-impregnated human bone allograft positioned as a next-generation dental bone graft substitute. During the COVID-19 pandemic, it turned its serum platform toward plasma therapy. Further development programs aim to extend serum therapy into wound healing, aesthetic applications and other regenerative indications. OrthoSera's flagship product, BoneAlbumin, has been used in multiple double-blind clinical trials and, according to the company, has demonstrated with up to seven years of follow-up that adding serum significantly improves clinical outcomes even in difficult cases. The company also runs the H4H research program, which aims to develop and validate a health-monitoring system based on infrared molecular fingerprinting. OrthoSera presents itself under the banner of "specialty pharma in tissue and plasma" and maintains a knowledge base of peer-reviewed publications, including studies on blood-derived products such as citrate platelet-rich plasma (CPRP) and hyperacute serum (HAS) and their effects on cellular senescence, inflammatory response and skin rejuvenation. The company is a private entity headquartered in Budapest, Hungary.

OrthoSera Medical Zrt. is a Hungarian specialty pharmaceutical company headquartered in Budapest. It positions itself as Hungary's leading blood-serum development company, built on the therapeutic use of the regenerative potential and power of blood serum. The company's scientific rationale rests on the more than 200 proteins found in blood serum, whose most important role, in OrthoSera's framing, is the activation of stem cells; matching the right serum derivative to the right indication is intended to initiate tissue remodeling and healing. OrthoSera has advanced three independently developed technologies to clinical use. In orthopedics, it developed stem-cell-activating bone and joint regeneration serums aimed at regenerating worn joints. In dentistry, it developed a serum-albumin-impregnated human bone allograft, presented as the next generation of dental bone graft substitutes. During the COVID-19 pandemic, the company applied its serum platform to plasma therapy. The company states that further developments will allow serum therapy to be extended to wound healing, aesthetic applications and other regenerative indications. Its flagship product, BoneAlbumin, has been used in several double-blind clinical trials. According to the company, these trials have demonstrated with up to seven years of follow-up that the addition of serum significantly improves clinical outcomes even in difficult cases. OrthoSera also runs the H4H research program, whose goal is to develop and validate a health-monitoring system based on infrared molecular fingerprinting. The company maintains a public knowledge base of scientific publications. These include a 2025 paper on bone grafting with albumin-impregnated bone allograft after odontogenic cyst removal, a 2024 study on culturing Hoffa fat pad mesenchymal stem/stromal cells on microcarrier suspension in a vertical wheel bioreactor for extracellular vesicle production, and a 2024 study on the effects of blood-derived products on cellular senescence and inflammatory response in skin rejuvenation. The latter examined citrate platelet-rich plasma (CPRP) and hyperacute serum (HAS), measuring markers such as γH2AX, p21 and p16, IL-6 and IL-8 levels, and collagen 1 expression in human dermal fibroblasts. OrthoSera operates as a private company based in Budapest, Hungary, and presents itself under the description "specialty pharma in tissue and plasma."

• OrthoSera develops and brings three independently developed technologies to clinical use: orthopedic joint regeneration serums, a dental serum-albumin-impregnated bone allograft, and plasma therapy for COVID-19.

• BoneAlbumin is used in multiple double-blind clinical trials, with up to seven years of follow-up showing improved clinical outcomes.

• 2024: Publication on culturing Hoffa fat pad mesenchymal stem/stromal cells on microcarrier suspension in a vertical wheel bioreactor for extracellular vesicle production.

• 2024: Publication on the effects of blood-derived products on cellular senescence and inflammatory response in skin rejuvenation.

• 2025: Publication on bone grafting with albumin-impregnated bone allograft after odontogenic cyst removal.

Specialty pharma in tissue and plasma; Hungary's leading blood-serum development company.

• BoneAlbumin

  Serum-albumin-impregnated human bone allograft for dental bone grafting, used in multiple double-blind clinical trials.

• Stem-cell-activating bone and joint regeneration serums

  Orthopedic serums intended to regenerate worn joints.

• Plasma therapy

  Serum-based plasma therapy developed for the fight against the COVID-19 pandemic.

1. 1OrthoSera official websiteorthosera.com
2. 2Effects of Blood-Derived Products on Cellular Senescence and Inflammatory Response: A Study on Skin Rejuvenation - OrthoSeraorthosera.com
3. 3OrthoSera Medical Zrt. (Hungary) - Wikidatawikidata.org